

Appendix H - 2018 FCDS Required Site Specific Data Items (SSDIs)

Below is the **List of 15 Site Specific Data Items (SSDI) Required by FCDS for 2018**. The list may be subject to changes. FCDS requires a small subset of the 136 total SSDIs available. The CoC/AJCC and SEER have broader SSDI Requirements. FCDS will monitor data from only 15 SSDIs; tracking for missing data and unknown values for any ‘analytic’ case reported. FCDS will accept and monitor data from these 15 new data items for missing data and unknown values for any ‘analytic’ case reported. SSDI data should be available for every ‘analytic’ case meeting AJCC Schema Criteria. Please refer to the *Site Specific Data Items Manual* for more information and specific coding instructions for each item.

FCDS Required	Item Number	Item Name	Start
C	3816	Brain Molecular Markers	2018
C	3817	Breslow Tumor Thickness	2018
C	3827	Estrogen Receptor Summary	2018
C	3835	Fibrosis Score	2018
C	3843	Grade Clinical	2018
C	3844	Grade Pathological	2018
C	3845	Grade Post Therapy	2018
C	3855	HER2 Overall Summary	2018
C	3890	Microsatellite Instability (MSI)	2018
C	3915	Progesterone Receptor Summary	2018
C	3920	PSA (Prostatic Specific Antigen) Lab Value	2018
C	3926	Schema Discriminator 1	2018
C	3927	Schema Discriminator 2	2018
C	3932	LDH Pretreatment Lab Value	2018

Appendix H - 2018 FCDS Required Site Specific Data Items (SSDIs)

Below is the **COMPLETE LIST of ALL Site Specific Data Items (SSDIs) available for 2018**. FCDS does not require all 136 available SSDIs. FCDS requires only a small subset of the 136 total SSDIs available. The CoC/AJCC and SEER have broader SSDI Requirements. FCDS will monitor data from only 15 SSDIs; tracking for missing data and unknown values for any ‘analytic’ case reported. Required SSDI data should be available for every ‘analytic’ case meeting Schema ID Criteria. Please refer to the *Site Specific Data Items Manual* for more information and specific coding instructions for each item.

FCDS Required	Item Number	Item Name	Start
	3801	Chromosome 1p: Loss of Heterozygosity (LOH)	
	3802	Chromosome 19q: Loss of Heterozygosity (LOH)	
	3803	Adenoid Cystic Basaloid Pattern	
	3804	Adenopathy	
	3805	AFP Post-Orchiectomy Lab Value	
	3806	AFP Post-Orchiectomy Range	
	3807	AFP Pre-Orchiectomy Lab Value	
	3808	AFP Pre-Orchiectomy Range	
	3809	AFP Pretreatment Interpretation	
	3810	AFP Pretreatment Lab Value	
	3811	Anemia	
	3812	B symptoms	
	3813	Bilirubin Pretreatment Total Lab Value	
	3814	Bilirubin Pretreatment Unit of Measure	
	3815	Bone Invasion	
C	3816	Brain Molecular Markers	2018
C	3817	Breslow Tumor Thickness	2018
	3818	CA-125 Pretreatment Interpretation	
	3819	CEA Pretreatment Interpretation	
	3820	CEA Pretreatment Lab Value	
	3821	Chromosome 3 Status	
	3822	Chromosome 8q Status	
	3823	Circumferential Resection Margin (CRM)	
	3824	Creatinine Pretreatment Lab Value	
	3825	Creatinine Pretreatment Unit of Measure	
	3826	Estrogen Receptor Percent Positive or Range	
C	3827	Estrogen Receptor Summary	2018
	3828	Estrogen Receptor Total Allred Score	
	3829	Esophagus and EGJ Tumor Epicenter	
	3830	Extranodal Extension Clin (non-Head and Neck)	
	3831	Extranodal Extension Head and Neck Clinical	
	3832	Extranodal Extension Head and Neck Pathological	
	3833	Extranodal Extension Path (non-Head and Neck)	
	3834	Extravascular Matrix Patterns	

Appendix H - 2018 FCDS Required Site Specific Data Items (SSDIs)

C	3835	Fibrosis Score	2018
	3836	FIGO Stage	
	3837	Gestational Trophoblastic Prognostic Scoring Index	
	3838	Gleason Patterns Clinical	
	3839	Gleason Patterns Pathological	
	3840	Gleason Score Clinical	
	3841	Gleason Score Pathological	
	3842	Gleason Tertiary Pattern	
C	3843	Grade Clinical	2018
C	3844	Grade Pathological	2018
C	3845	Grade Post Therapy	2018
	3846	hCG Post-orchietomy Lab Value	
	3847	hCG Post-orchietomy Range	
	3848	hCG Pre-orchietomy Lab Value	
	3849	hCG Pre-orchietomy Range	
	3850	HER2 IHC Summary	
	3851	HER2 ISH Dual Probe Copy Number	
	3852	HER2 ISH Dual Probe Ratio	
	3853	HER2 ISH Single Copy Number	
	3854	HER2 ISH Summary	
C	3855	HER2 Overall Summary	2018
	3856	Heritable Trait	
	3857	High Risk Cytogenetics	
	3858	High Risk Histologic Features	
	3859	HIV Status	
	3860	International Normalized Ratio Prothrombin Time	
	3861	Ipsilateral Adrenal Gland Involvement	
	3862	JAK2	
	3863	Ki-67	
	3864	Invasion Beyond Capsule	
	3865	KIT Gene Immunohistochemistry	
	3866	KRAS	
	3867	LDH Post-Orchiectomy Range	
	3868	LDH Pre-Orchiectomy Range	
	3869	LDH Pretreatment Level	
	3870	LDH Upper Limits of Normal	
	3871	LN Assessment Method Femoral-Inguinal	
	3872	LN Assessment Method Para-aortic	
	3873	LN Assessment Method Pelvic	
	3874	LN Distant Assessment Method	
	3875	LN Distant: Mediastinal, Scalene	

Appendix H - 2018 FCDS Required Site Specific Data Items (SSDIs)

	3876	LN Head and Neck Levels I-III	
	3877	LN Head and Neck Levels IV-V	
	3878	LN Head and Neck Levels VI-VII	
	3879	LN Head and Neck Other	
	3880	LN Isolated Tumor Cells (ITC)	
	3881	LN Laterality	
	3882	LN Positive Axillary Level I-II	
	3883	LN Size	
	3884	LN Status Femoral-Inguinal, Para-aortic, Pelvic	
	3885	Lymphocytosis	
	3886	Major Vein Involvement	
	3887	Measured Basal Diameter	
	3888	Measured Thickness	
	3889	Methylation of O6-Methylguanine-Methyltransferase	
C	3890	Microsatellite Instability (MSI)	2018
	3891	Microvascular Density	
	3892	Mitotic Count Uveal Melanoma	
	3893	Mitotic Rate Melanoma	
	3894	Multigene Signature Method	
	3895	Multigene Signature Results	
	3896	NCCN International Prognostic Index (IPI)	
	3897	Number of Cores Examined	
	3898	Number of Cores Positive	
	3899	Number of Examined Para-Aortic Nodes	
	3900	Number of Examined Pelvic Nodes	
	3901	Number of Positive Para-Aortic Nodes	
	3902	Number of Positive Pelvic Nodes	
	3903	Oncotype Dx Recurrence Score-DCIS	
	3904	Oncotype Dx Recurrence Score-Invasive	
	3905	Oncotype Dx Risk Level-DCIS	
	3906	Oncotype Dx Risk Level-Invasive	
	3907	Organomegaly	
	3908	Percent Necrosis Post Neoadjuvant	
	3909	Perineural Invasion	
	3910	Peripheral Blood Involvement	
C	3911	Peritoneal Cytology	2018
	3913	Pleural Effusion	
	3914	Progesterone Receptor Percent Positive or Range	
C	3915	Progesterone Receptor Summary	2018
	3916	Progesterone Receptor Total Allred Score	
	3917	Primary Sclerosing Cholangitis	

Appendix H - 2018 FCDS Required Site Specific Data Items (SSDIs)

	3918	Profound Immune Suppression	
	3919	Prostate Pathological Extension	
C	3920	PSA (Prostatic Specific Antigen) Lab Value	2018
	3921	Residual Tumor Volume Post Cytoreduction	
	3922	Response to Neoadjuvant Therapy	
	3923	S Category Clinical	
	3924	S Category Pathological	
	3925	Sarcomatoid Features	
C	3926	Schema Discriminator 1	2018
C	3927	Schema Discriminator 2	2018
	3928	Schema Discriminator 3	
	3929	Separate Tumor Nodules	
	3930	Serum Albumin Pretreatment Level	
	3931	Serum Beta-2 Microglobulin Pretreatment Level	
C	3932	LDH Pretreatment Lab Value	2018
	3933	Thrombocytopenia	
	3934	Tumor Deposits	
	3935	Tumor Growth Pattern	
	3936	Ulceration	
	3937	Visceral and Parietal Pleural Invasion	